News
Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year ...
Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.
IDMC's formal review concluded that the therapy met the pre-defined superiority criteria, showing significant efficacy.
1h
Capital Market on MSNBiocon's biologics arm gets regulatory approval in EU for Denosumab biosimilarsDenosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear ...
The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...
Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best growth stocks to invest in for the next 5 years. On Monday, the ...
Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...
Regeneron secured accelerated FDA approval for Lynozyfic, a therapy targeting relapsed or refractory multiple myeloma. The ...
The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...
Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results